AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform that the officials of the Company will be participating in the investor meeting.08-06-2023
08-06-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform that the officials of the Company will be participating in the investor meeting.07-06-2023
AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We bring to your kind notice that the Company has received the letters from the shareholders informing about the loss of share certificates and requested for issue of duplicate share certificates.05-06-2023
Aurobindo Pharma's P Sarath Reddy becomes approver in Delhi liquor case
ED said that Reddy will voluntarily disclose all the irregularities in making as well as implementing the liquor policy in Delhi02-06-2023
AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We bring to your kind notice that the Company has received the letters from the shareholders informing about the loss of share certificates and requested for issue of duplicate share certificates01-06-2023
Hold Aurobindo Pharma; target of Rs 665: KR Choksey
KR Choksey recommended hold rating on Aurobindo Pharma with a target price of Rs 665 in its research report dated May 31, 2023.01-06-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Please refer to our letter dated May 19, 2023, wherein we intimated about the schedule of Investors/ Analysts call on May 29, 2023. We are attaching herewith the Transcript of the said analyst / investor call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2023, and the same is being uploaded on the website of the Company and is available in the following web link. https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/conference-call-transcripts/01-06-2023
Neutral Aurobindo Pharma; target of Rs 600: Motilal Oswal
Motilal Oswal recommended Neutral rating on Aurobindo Pharma with a target price of Rs 600 in its research report dated May 29, 2023.31-05-2023
Brokerages give thumbs up to Aurobindo's investment plans, but valuations pinch
While most brokerages are positive on Aurobindo Pharma's strong investments in biosimilars, Pen-G, injectables and peptides, the current stock valuation remains a key concern for others.30-05-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing copies of newspaper advertisement of the financial results of the company for the fourth quarter and year ended March 31, 2023, as published in Business Standard and Nava Telagana on May 29, 2023.29-05-2023